Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:13 2024-06-05 EDT After market 15:58:01
29.64 EUR +1.54% Intraday chart for Fresenius SE & Co. KGaA 29.83 +0.64%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
FRESENIUS SE : JP Morgan gives a Neutral rating ZD
Dpa-AFX Overview: COMPANIES from 05.06.2024 - 15:15 DP
FRESENIUS SE : Berenberg reiterates its Buy rating ZD
FRESENIUS SE : Barclays reaffirms its Buy rating ZD
Fresenius raises targets for hospital business - shares up DP
FRESENIUS SE : Jefferies reaffirms its Buy rating ZD
Fresenius driven by higher Helios targets DP
FRESENIUS SE : Jefferies gives a Buy rating ZD
Transcript : Fresenius SE & Co. KGaA - Analyst/Investor Day
Fresenius lifts 2024 targets for private healthcare unit Helios RE
Fresenius chart breakout fails before capital market day DP
FMC briefly burdened by research success in the fight against diabetes DP
FMC, Fresenius and Davita rise after Ozempic news DP
Ailing hospitals slow down German medical technology sector DP
JPMorgan raises target for Fresenius SE to 37.60 euros - 'Neutral' DP
FRESENIUS SE : JP Morgan remains Neutral ZD
What does the new atlas mean for the 'hospital jungle'? DP
Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative MT
Launch of new quality atlas for hospitals DP
Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability MT
Union demands Lauterbach approach the federal states on hospital reform DP
Dobrindt demands approach to federal states on hospital reform DP
Lauterbach's 'revolution' for clinics on the way DP
Cabinet launches hospital reform DP
Cabinet to get hospital reform underway DP
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.64 EUR
Average target price
37.16 EUR
Spread / Average Target
+25.38%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability